7,244 Shares of Illumina, Inc. $ILMN Bought by Leo Wealth LLC

Key Points

• Leo Wealth LLC purchased 7,244 Illumina shares worth approximately $1.98 million in the third quarter. Institutional investors and hedge funds collectively own 89.42% of the company.
• Illumina reported quarterly results above expectations, with EPS of $1.31 versus the $1.23 consensus and revenue of $1.16 billion, up 9.4% year over year. The company issued fiscal 2026 EPS guidance of $5.30–$5.40.
• Analyst sentiment remains mixed: the consensus rating is “Hold” with a $234.41 target price, while the stock recently opened at $271.04. Insiders have sold more than 2 million shares worth approximately $436.5 million over the past 90 days.

Leo Wealth LLC purchased a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,244 shares of the life sciences company's stock, valued at approximately $1,981,000.

Several other institutional investors have also made changes to their positions in the stock. Fiduciary Financial Advisors purchased a new stake in Illumina in the 2nd quarter worth approximately $26,000. MCF Advisors LLC boosted its stake in shares of Illumina by 172.4% during the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company's stock valued at $28,000 after buying an additional 100 shares during the period. Keating Financial Advisory Services Inc. acquired a new stake in shares of Illumina during the 2nd quarter valued at $32,000. Rakuten Securities Inc. acquired a new stake in shares of Illumina during the 2nd quarter valued at $33,000. Finally, Elevation Wealth Partners LLC grew its holdings in shares of Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company's stock valued at $43,000 after acquiring an additional 84 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Performance

ILMN opened at $271.04 on Tuesday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The company has a market cap of $40.93 billion, a PE ratio of 50.57, a price-to-earnings-growth ratio of 3.82 and a beta of 1.41. The stock has a 50-day moving average of $241.80 and a 200-day moving average of $173.01. Illumina, Inc. has a 52-week low of $94.00 and a 52-week high of $309.35.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period last year, the business earned $1.19 EPS. The firm's revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ILMN. Zacks Research downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 1st. Stifel Nicolaus increased their price objective on Illumina from $155.00 to $225.00 and gave the stock a "buy" rating in a report on Friday, July 31st. Sanford C. Bernstein reissued a "market perform" rating and set a $215.00 price objective on shares of Illumina in a research report on Friday, July 31st. JPMorgan Chase & Co. lifted their price objective on Illumina from $220.00 to $230.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. Finally, Leerink Partners upped their target price on Illumina from $220.00 to $300.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 29th. Ten investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $234.41.

Insider Buying and Selling

In other Illumina news, Director Keith Meister sold 457,858 shares of the stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the transaction, the director owned 2,372,694 shares in the company, valued at $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 2,061,850 shares of company stock worth $436,479,102 in the last 90 days. Company insiders own 2.90% of the company's stock.

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.